KalGene Pharmaceuticals Closes Financing to Support the Clinical Development of its Alzheimer's Therapeutic

TORONTO, ON  KalGene Pharmaceuticals announced the closing of a Series A financing to support the advancement of its lead Alzheimer's therapeutic program. The syndicated investment was led by Lumira Capital and included participation from Anges Québec, Anges Québec Capital, Accel-Rx Health Sciences Accelerator and a number of Canadian family offices. In addition to the equity financing the company has also received significant financial support from leading Foundations focused on neurodegenerative diseases. Proceeds from these combined funding sources will support the development of KalGene's lead Alzheimer's therapeutic candidate.

We’ve followed the development of this program for many years and have been working directly with the team for the last year on this opportunity. During the past year, one of Lumira’s advisors, Dr. John Gillard, joined the company as Vice President Drug Development to advance the lead product to the clinic.
— Daniel Hetu, Managing Director at Lumira Capital

For the full press release click here

Previous
Previous

OBIO 2017 Annual Public Meeting Features Dr. Edward Abrahams, President of the Personalized Medicine Coalition, and Launch of Latest Report, ‘Bridging the Talent Gap’

Next
Next

New OBIO Report: Bridging the Talent Gap